henan lingrui pharmaceutical plans to acquire Silver Valley Pharmaceuticals for 0.782 billion. Traditional Chinese medicine patch and plaster leading the cross-border pharmaceutical market | Quick reading announcement

①Henan Lingrui Pharmaceutical intends to acquire all the equity of Silver Valley Pharmaceutical for 0.782 billion yuan, entering the market of innovative drugs in chemical medicine. ②According to Mononucleosis Medical Data, Silver Valley Pharmaceutical's sales in 2023 exceeded 0.4 billion yuan, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of Class 1 new drug Biti Cong quickly. ③If the acquisition of Silver Valley Pharmaceutical proceeds smoothly, the company's previously set stock-based incentive unlocking target may be difficult to achieve or significantly reduced.

cls.cnDec 4 10:07 ET

Henan Lingrui Pharmaceutical discloses a stock-based incentive plan Unveiling conditions: average annual double-digit growth in non-GAAP net income | Speed ​​reading announcement

①Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, slightly lowering the assessment target compared to the previous incentive plan, but still maintaining a double-digit non-GAAP performance assessment requirement. ②In addition to Henan Lingrui Pharmaceutical, tibet cheezheng tibetan medicine has also previously announced an employee stock ownership plan with higher assessment targets, and the industry expects bone health to be a high-potential category in the out-of-hospital market.

cls.cnNov 29 10:25 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

0.629 billion yuan! A village investment acquired 5% equity of Wang Jianguo's controlled Kids' King.

① Wang Jianguo, the founder of Child King, the concerted actor, plans to transfer 5% of the shares to Yicun Investment at a price of 10 yuan per share, with a total price reaching 0.629 billion yuan; ② Wang Jianguo has successively harvested two IPOs, one is Child King, and the other is Huitongda. At the same time, he is also a private placement big shot, establishing Xingnahe Capital, investing in Feihe, AVIC Lithium Battery, Jiangxiaobai and other enterprises.

cls.cnNov 27 02:17 ET

Aimer Group: Cost reduction and efficiency improvement cannot stop the decline in demand. The end of the third quarter is a conventional high point for inventory｜Directly hitting the earnings conference.

① Aimer Co., Ltd. stated at the earnings conference that the end of the third quarter is a relative high point of inventory in the company's regular operation, mainly for stocking up for the sales peak in the fourth quarter; ② The main reason for the loss in the third quarter is the significant drop in market demand, and the company's revenue decline is substantial, while the efforts to increase efficiency and reduce costs could not offset the impact of the revenue decrease; ③ The company's sportswear sector is still in its infancy, and its contribution to performance is not significant.

cls.cnNov 19 04:05 ET

Major asset restructuring changes, jinfa labi intends to reduce the acquisition of the target equity to 51% | Speed ​​reading announcement

① Jinfa Labi has terminated the major asset restructuring, changing to the acquisition of 51% equity in Zhuhai Hanfei and Zhongshan Hanfei, which does not constitute a major asset restructuring. ② Jinfa Labi has incurred net income losses for two consecutive years, with revenue of 0.139 billion yuan in the first three quarters, down 7.63% year-on-year, and a net income attributable to shareholders of -9.9525 million yuan.

cls.cnNov 17 08:46 ET